Skip to main content

Table 4 Summary of the adverse events reported by two or more subjects in the single oral dose study

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

   GSK2239633   
  Placebo (n = 24) n (%) 150 mg (n = 8) n (%) 300 mg (n = 8) n (%) 600 mg (n = 8) n (%) 900 mg (n = 8) n (%) 1200 mg (n = 8) n (%) 1500 mg (n = 8) n (%) 1200 mg (Fed) (n = 8) n (%) Placebo (Fed) (n = 4) n (%) Total (n = 24) n (%)
Any event 9 (38) 4 (50) 5 (63) 5 (63) 1 (13) 2 (25) 3 (38) 2 (25) 1 (25) 19 (79)
Headache 3 (13) 2 (25) 0 0 1 (13) 1 (13) 1 (13) 0 0 5 (21)
Diarrhoea 2 (8) 0 2 (25) 1 (13) 1 (13) 0 2 (25) 0 0 4 (17)
Rhinitis 1 (4) 1 (13) 0 0 0 0 1 (13) 0 0 2 (8)
Abdominal pain 0 0 0 0 0 0 1 (13) 0 0 1 (4)